Travere Therapeutics, Inc. Common Stock (TVTX)
Travere Therapeutics, Inc. (TVTX) is a biotechnology company focused on developing and commercializing therapies for rare andимmunologic diseases. The company's portfolio includes treatments aimed at addressing unmet medical needs in kidney, liver, and rare neurological disorders. Founded with a mission to improve patient outcomes, Travere leverages its expertise in novel drug discovery and development to bring targeted therapies to market.
Company News
Multiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.
Travere Therapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA seeking approval of FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney condition. If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS.
Travere (TVTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
A mixed trial could hurt a kidney drug's chances of full approval.
Travere Therapeutics and Vera Therapeutics are also developing treatments for rare kidney disease